Johns Hopkins Medicine laboratory scientists say they have developed a potential new way to treat a variety of rare genetic ...

With the help of mRNA technology proven effective during the COVID era, researchers are now closer than ever to creating ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...

Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company ...

mRNA cancer vaccines work by giving the body ... send it to the pharmaceutical company, and they design a personalized vaccine that’s bespoke to that patient’s cancer. That vaccine is not ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial ...

The New Normal Five years ago, COVID-19 was declared a global pandemic, marking the official onset of a healthcare crisis ...

Therefore, mRNA vaccine design, formulation, and delivery will need to be further improved to compete in this area; and self-amplifying RNAs (saRNA) may become a preferred platform, due to ...